Clinical Trial Finder

Ask About Participating in This Study

Genetic TherapyEnrolling

Study to evaluate KB407 in adults with cystic fibrosis, protocol number Krystal Biotech KB407-02

The following information will be used to determine eligibility for this study. Fill out the form and click “Preview Message.” This will draft an email you can send directly to the Research Coordinator. Please note, this does not guarantee entry into this particular study.

* indicates required field

Personal Information

Your Full Name (required) Please enter your name

Your Email (required) Please enter a valid email address

Your Phone Number (required) Please enter a valid phone number

Study Location (required) Please choose a location

Additional Information:

Add more details about who you are and how you would like to be contacted (e.g. phone, text, email).

Required: I certify that I am at least 18 years old. I understand that I am authorizing Cff.org to send an e-mail from my personal e-mail account to a research coordinator. My email may contain sensitive information if I include it. I know that sending this e-mail is entirely optional and does not affect my ability to use other information on this website or to independently contact research sites separate from this website. I further understand that the Cystic Fibrosis Foundation does not accept responsibility for whether this e-mail reaches its intended recipient and what the intended recipient does with the information contained within this e-mail. The Cystic Fibrosis Foundation does not retain any information provided in this email in any form. Please check the box to continue

Preview Message

(this will open in your email program)

Genetic TherapyEnrolling

Study to evaluate KB407 in adults with cystic fibrosis, protocol number Krystal Biotech KB407-02

This study will evaluate safety and tolerability of ascending doses of nebulized KB407, a gene therapy intended to deliver a new, correct copy of the CFTR gene (DNA) to cells in adults with cystic fibrosis.

Age:

18 Years and Older
Mutation(s):

No Mutation Requirement
FEV1% Predicted:

50 to 100%
Number of Visits:

10
Length of Participation:

3 months

CONTACT THE CLINICAL TRIAL NAVIGATOR

Get personalized assistance and answers to your clinical trial questions.

Learn More

Get email updates about clinical trials that matter to you.

Email address Please enter a valid email address

Check the Drug Development Pipeline

We’re attacking CF from every angle. Learn about the status of CF drugs in development.

Learn More

Page Title

Ask About Participating in This Study

Personal Information

* Study Location (required) Please choose a location

Additional Information:

Related Topics

Study Location (required) Please choose a location